TECLISTAMAB

The PBAC recommended that teclistamab be listed on the PBS for the treatment of patients with relapsed or refractory multiple myeloma (RRMM) who have received at least 3 prior lines of therapy. The PBAC considered that the use of teclistamab would result in similar outcomes (both in terms of efficacy and safety) as elranatamab, which is currently PBS listed for the treatment of RRMM in the same population requested for teclistamab. The PBAC welcomed the input from individuals, health care professionals and organisations. The PBAC noted that the input highlighted the continued need for new and effective therapies for patients with RRMM. The PBAC noted the positive responses to treatment for patients who have accessed teclistamab via clinical trials and the substantial improvements that treatment offered to their quality of life.

The PBAC considered that the requested restrictions, which aligned with the elranatamab restrictions, were appropriate. The PBAC advised that a flow on change to the elranatamab restrictions would be required to allow switching between teclistamab and elranatamab in the absence of disease progression (e.g. in case of intolerance to one drug). The PBAC also considered that the price of teclistamab should equal that of elranatamab and, as such, the listing of teclistamab on the PBS should have little to no impact on overall costs for the PBS. The PBAC advised that teclistamab should join the arrangement currently in place for elranatamab to manage financial risks with no increase in the existing spending limits.